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Abstract
Experimental studies targeting traumatic brain injury (TBI) have reported that erythropoietin (EPO) is an endogenous
neuroprotectant in multiple models. In addition to its neuroprotective effects, it has also been shown to enhance reparative
processes including angiogenesis and neurogenesis. Based on compelling pre-clinical data, EPO was tested by the
Operation Brain Trauma Therapy (OBTT) consortium to evaluate therapeutic potential in multiple TBI models along with
biomarker assessments. Based on the pre-clinical TBI literature, two doses of EPO (5000 and 10,000 IU/kg) were tested
given at 15min after moderate fluid percussion brain injury (FPI), controlled cortical impact (CCI), or penetrating
ballistic-like brain injury (PBBI) with subsequent behavioral, histopathological, and biomarker outcome assessments.
There was a significant benefit on beam walk with the 5000 IU dose in CCI, but no benefit on any other motor task across
models in OBTT. Also, no benefit of EPO treatment across the three TBI models was noted using the Morris water maze to
assess cognitive deficits. Lesion volume analysis showed no treatment effects after either FPI or CCI; however, with the
5000 IU/kg dose of EPO, a paradoxical increase in lesion volume and percent hemispheric tissue loss was seen after PBBI.
Biomarker assessments included measurements of glial fibrillary acidic protein (GFAP) and ubiquitin C-terminal
hydrolase-L1 (UCH-L1) in blood at 4 or 24 h after injury. No treatment effects were seen on biomarker levels after FPI,
whereas treatment at either dose exacerbated the increase in GFAP at 24 h in PBBI but attenuated 24–4 h delta UCH-L1
levels at high dose in CCI. Our data indicate a surprising lack of efficacy of EPO across three established TBI models in
terms of behavioral, histopathological, and biomarker assessments. Although we cannot rule out the possibility that other
doses or more prolonged treatment could show different effects, the lack of efficacy of EPO reduced enthusiasm for its
further investigation in OBTT.
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Introduction
Traumatic brain injury (TBI) affects up to 2% of the pop-ulation per year and is a serious clinical and common public
health problem worldwide.1–4 TBI is a major cause of death and
disability throughout the world, and recently there has been an
increase in the prevalence of TBI in the elderly because of falls and
other traumatic insults. TBI is also the signature injury of modern
warfare with*20% of US soldiers returning from Afghanistan and
Iraq with evidence of mild TBI.
The consequences of TBI are multifactorial and can include
long-term cognitive, behavioral, or physical deficits including post-
concussion syndromes. Although much research has been con-
ducted to clarify the complex pathophysiology of TBI, neuroprotective
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treatments have not been successfully translated to the clinic.5
There are various proposed reasons for this failure, including the
complexity and heterogeneous nature of clinical TBI, as well as
other limitations regarding adequate pre-clinical data to support the
translation of therapies into the clinic.
A review of the experimental TBI literature suggests that
erythropoietin (EPO) is a promising future therapy.6–15 Subsequent
to the selection and testing of EPO in Operation Brain Trauma
Therapy (OBTT), however, a recent single-center clinical trial in
EPO in severe TBI was completed that did not show efficacy.16
Thus, controversy exists with regard to the potential efficacy of
EPO, including effects across type and/or severity of injury.
EPO is a member of the type 1 cytokine superfamily consisting
of a 165-amino acid sequence.17 This hormone is produced by
the kidneys and leads to production of erythrocytes.17 It has been
identified in brain astrocytes, and expression has been shown to
increase under certain pathological conditions including hypoxia.18
EPO expression has been documented in biopsies of the human
hippocampus, amygdala, and temporal cortex with hypoxia in-
ducible factor-2 being the major regulator of EPO expression
during hypoxia.19
EPO has been shown to be neuroprotective in multiple patho-
logical conditions including ischemia, hypoxia, neurotoxic and
excitotoxic stress in the nervous system.20 Also, EPO receptors
have been identified in the brain, and their activation can mediate
several potentially protective effects after brain injury.21 In models
of TBI, EPO doses of 5000 IU/kg have produced recovery of
neurological function and tissue preservation after TBI.21 In addi-
tion to dose response studies, the beneficial effects of EPO ad-
ministration appear to be optimal within 6 h after injury, although
some preservation has been seen in EPO given as late as 24 h after
injury.6,7,9,22
In addition to preserving tissue integrity, EPO has also been
shown to promote reparative events including angiogenesis and
neurogenesis after TBI.6 Subsequent studies have clarified that the
effect of EPO on regenerative processes occurs through metallo-
proteinase 2 and 9 and/or other specific cell signaling cascades.23–26
The fact that EPO has been shown to be beneficial in multiple
TBI models and produce long-term improvements in behavioral
outcome makes it potentially promising for additional clinical
testing—even with a negative clinical trial in severe TBI. Testing of
EPOwould also reflect on the ability of OBTT to predict efficacy of
a therapy in a clinical trial of severe TBI.
Thus, the purpose of this study was to use the OBTT platform to
test this therapy across three injury models for efficacy. We tested a
dose of EPO (5000 IU/kg) that has shown efficacy in new treatment
pre-clinical studies and a high dose (10,000 IU/kg) to explore whe-
ther there is a dose response in the protective efficacy. We assessed
clinically relevant behavioral outcomemeasures includingmotor and
cognitive function as well as circulating blood biomarker levels. Our
studies provide novel data regarding the treatment effects of EPO
across the various injury models as well as unique biomarker sig-
natures for EPO treatment. Consistent with the clinical trial but not
the pre-clinical literature, our studies with EPO did not show a
positive effect in improving behavioral, histopathological, or bio-
marker outcomes across the OBTT consortium.
Methods
This treatment article is the third in a series of articles published
by the OBTT consortium in this issue of the Journal of Neuro-
trauma; thus, the methodology will only be briefly stated. Readers
are referred back to the first therapy manuscript in this issue—
namely, the article assessing the effects of nicotinamide—for more
detailed methods.27
Male Sprague-Dawley rats (300–350 g) were used for all ex-
periments. Animal care was in accordance with the guidelines set
forth by the Institutional Animal Care and Use Committee, the
United States Army, and the National Institutes of Health (NIH)
Guide for the Care and Use of Laboratory Animals. Rats were
housed in a temperature-controlled room (22C) with a 12-h light/
dark cycle. All animals had access to food and water ad libitum,
except where noted in Methods.
Animal models
Fluid percussion brain injury (FPI) model—Miami. Rats
were anesthetized (70%N2O/30%O2, 1–3% isoflurane) 24 h before
injury and surgically prepared for parasagittal FPI as described
previously.28 A right craniotomy was performed, and a plastic in-
jury tube was placed over the exposed dura. The scalp was sutured
closed, and the rats returned to their home cage. After fasting
overnight, the rats were anesthetized, tail artery and jugular vein
catheters were placed, the rat was intubated and underwent a
moderate FPI. Blood gases were obtained while the animals were
intubated, and levels were measured from arterial samples 15min
before and 30min after moderate FPI.
FPI served as our sentinel model for assessing the effects of
therapies on acute physiological parameters including hemody-
namics and blood gases, and the 30min time point provided an
assessment of the effect of TBI and treatment at 15min after drug
administration. Sham rats underwent all procedures except for the
FPI. After TBI, the rats were returned to their home cages with food
and water ad libitum.
Controlled cortical impact (CCI) model—Pittsburgh. Rats
were anesthetized (2–4% isoflurane in 2:1 N2O/O2), intubated, and
placed in a stereotaxic frame. A parasagittal craniotomy was per-
formed, and rats were impacted with the CCI device (Pittsburgh
Precision Instruments, Inc.) at a depth of 2.6mm at 4m/sec.29 The
scalp was sutured closed, and rats were returned to their home
cages. Sham rats underwent all procedures except for the CCI.
Penetrating ballistic-like brain injury (PBBI) model—Walter
Reed Army Institute of Research (WRAIR). PBBI was per-
formed as described previously.30 Briefly, anesthetized (isoflurane)
rats were placed in a stereotaxic device for insertion of the PBBI
probe into the right frontal cortex at a depth of 1.2 cm. The pulse
generator was activated, and the elliptical balloon was inflated to
produce a temporary cavity in volume equal to 10% of the total
brain volume. After probe withdrawal, the craniotomy was sealed
with sterile bone wax, and wounds were closed. Sham rats under-
went all procedures except for the PBBI probe insertion.
Drug administration
EPO was purchased at each site’s pharmacy (Procrit, Amgen) and
kept refrigerated until use. A new vial of EPO was used each day,
because the drug is preservative free. Rats received one of two in-
travenous (IV) doses—5000 IU/kg or 10,000 IU/kg 15min after in-
jury over a 5min period.The 5000 IU/kgdosing regimenwas selected
based on previous pre-clinical investigations.6 Physiologic salinewas
administered as a control. Sham operated rats received no treatment.
The drug was prepared at each site by an individual who did not
perform the injury, behavioral testing, or histopathological analysis.
Group numbers for each study site are summarized in Table 1.
Biomarker serum sample preparation
Blood samples (0.7mL) were collected at 4 h and 24 h post-
injury as well as before perfusion for histological analysis. Blood
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withdrawals for the FPI and PBBI models were taken from an
indwelling jugular catheter at 4 h and 24 h after TBI and via tail vein
at identical time points after CCI. Blood samples at the terminal
end-point were taken via cardiac puncture for all models. Blood
was prepared as described previously for serum in FPI and PBBI
and plasma in CCI.31 All samples were shipped via FedEx priority
overnight (on dry ice) to Banyan Biomarkers, Inc., for further
analysis of biomarker levels.
Primary outcome metrics
The overall approach to outcome testing, scoring, and details
of the specific outcome methods and metrics are described in detail
in the first therapy article within this issue.27 These outcomes in-
clude (1) sensorimotor, (2) cognition, (3) neuropathology, and (4)
biomarkers.
Sensorimotor methods.
FPI model. The spontaneous forelimb or cylinder test was
used to determine forelimb asymmetry as described previously.32
The gridwalk task was used as well to determine forelimb and
hindlimb sensorimotor integration. Rats were assessed at 7 days
post-injury.
CCI model. Two sensorimotor tests were used—the beam
balance task and the beam walking task, as described previous-
ly.33 Rats were assessed during the initial 5 consecutive days post-
CCI.
PBBI model. A modified neuroexamination was used to
evaluate rats at 1, 7, 14, and 21 days post-injury.34 Additional
assessments of motor coordination and balance used the fixed-
speed rotarod task on days 7 and 10 post-injury.30
Cognitive testing. All sites used the Morris water maze
(MWM) for cognitive testing. Spatial learning was assessed over
*13–18 days post-injury depending on the site. Primary outcomes
included path latency (all sites), swim distance (only FPI), and
thigmotaxis (only PBBI). All three sites also included a probe trial
to determine retention of the platform location after removal. In
addition, theMiami site tested the rats for working memory on days
20 and 21, and both the Pittsburgh and WRAIR sites used a visible
platform task on days 19–20. Detailed descriptions of cognitive
testing are described elsewhere.27,35
Histopathological assessments. After behavioral testing,
rats were anesthetized and perfused with 4% paraformaldehyde
(FPI and PBBI) or 10% phosphate-buffered formalin (CCI).
Brains were processed for paraffin embedding or frozen sec-
tioning. Coronal slices were stained with hematoxylin and eosin
for lesion volume (all sites) and cortical (FPI) or hemispheric
(CCI and PBBI) tissue volume as described previously.27 Both
lesion volume and tissue volume loss were expressed as a per-
cent of the contralateral (‘‘noninjured’’) hemisphere (CCI and
PBBI) or as a percent of the contralateral cortex (FPI). In FPI,
lesion volume and tissue volume loss were expressed as a per-
cent of the contralateral cortex rather than the entire hemisphere
given the small lesion size and established standard protocol in
Miami.
Biomarker assessments. Blood levels of neuronal and glial
biomarkers, namely ubiquitin C-terminal hydrolase-L1 (UCH-L1)
and glial fibrillary acidic protein (GFAP) were measured by
enzyme-linked immunosorbent assay (ELISA) at 4 h and 24 h post-
injury. Please see Mondello and associates31 and Shear and col-
leagues27 for a more detailed description of the ELISA and other
biomarker-related methods used in these studies.
Primary outcome metrics for the biomarkers consisted of (1)
evaluating the effect of drug treatment on blood biomarker levels at
24 h post-injury and (2) the effect of drug treatment on the differ-
ence between 24 h and 4 h (delta 24–4 h) levels. We chose these two
primary outcomes for different reasons: 24 h post-injury represents
an optimal time window for evaluating any substantial effects of a
drug on biomarker levels. On the other hand, delta 24–4 h has a
great appeal because assessment of drug effect will account for the
initial severity of the injury while allowing each rat to serve as its
own control.
For the sake of completeness, GFAP and UCH-L1 levels at 4 h
post-injury were also reported. This information helps to charac-
terize the release pattern of biomarkers in the acute phase and the
relation to injury severity and may have potential clinical impli-
cations regarding the assessment of the temporal window of bio-
markers for detecting a drug effect.
OBTT outcome scoring matrix
To determine therapeutic efficacy across all models, a scoring
matrix summarizing all of the primary outcome metrics (sensori-
motor, cognition, neuropathology [lesion volume, cortical vol-
ume]), and biomarker (24 h and delta 24–4 h) assessments was
developed. A maximum of 22 points at each site can be achieved.
Details of the OBTT Scoring Matrix are provided in the initial
companion article in this issue.35
Statistical analysis
Normality was assessed, and data are expressed as mean –
standard error of the mean or median (interquartile range), as ap-
propriate. Physiological data, contusion and tissue volumes, and
probe trial were analyzed using a one-way analysis of variance
(ANOVA). One-way ANOVA or repeated measures ANOVA was
used to analyze motor tasks as appropriate, depending on the spe-
cifics of the data collection. Repeated measures ANOVA was also
used to analyze data for the hidden platform and working memory
tasks.
Post hoc analysis, when appropriate, used the Student-
Newman Keuls (SNK) or Tukey test. The differences in bio-
marker concentration among the groups in each TBI model were
analyzed with the Kruskal-Wallis test followed by post hoc
comparisons applying Mann-Whitney U and Bonferroni cor-
rection.
All statistical tests were two-tailed and a p value <0.05 was
considered significant. Statistical analyses were conducted using
SAS (SAS version [9.2] of the SAS System. ª 2002–2008 by SAS
Institute Inc., Cary, NC) and Sigmaplot v.11.0 (Systat Software,
Inc., Chicago, IL).
Table 1. Summary of Experimental Group Sizes
for Traumatic Brain Injury/Erythropoietin Study
Group Sham TBI-Vehicle
TBI-5000
IU/kg
TBI-10,000
IU/kg N
FPI - Miami 9 10 10 10 39
CCI - Pittsburgh 12 12 12 12 48
PBBI - WRAIR 9 15 14 15 53
TBI, traumatic brain injury; FPI, fluid percussion injury; CCI, controlled
cortical impact; PBBI, penetrating ballistic-like brain injury; WRAIR,
Walter Reed Army Institute of Research.
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Results
Physiological parameters
Physiological parameters, including mean arterial blood pres-
sure (MABP), PaO2, PaCO2, and blood pH, taken in the FPI model
(Miami) are provided in Table 2. Physiological variables were ta-
ken before and after TBI. All physiological values were within
normal range, and there were no significant differences between the
various experimental groups in terms of MABP, PaO2, PaCO2, and
blood pH. There was no effect of treatment on acute physiology or
blood gases.
Sensorimotor parameters
FPI model. Rats were assessed using the cylinder task for
spontaneous forelimb use (Fig. 1A). One-way ANOVA was not
significant between groups ( p = 0.89). All injured rats exhibited
contralateral forelimb placing deficits with an asymmetry index of
<0.5. There was no improvement on this task versus vehicle (VEH)
treatment with either dose of EPO.
Sensorimotor integration was analyzed using the gridwalk test
(Fig. 1B). Each forelimb and hindlimb is assessed independently
for foot faults. Data are expressed as a percent of total steps for each
limb. One-way ANOVA for both contralateral forelimb and hind-
limb were not different between groups ( p= 0.658 and p = 0.715,
respectively). Similar findings were found for ipsilateral forelimb
and hindlimb placement. One-way ANOVA for ipsilateral forelimb
and hindlimb were not significant for group ( p= 0.933 and
p = 0.886, respectively). EPO treatment did not improve sensori-
motor function as assessed by the gridwalk task.
CCI model. For the beam balance test, a two-way repeated
measures ANOVA revealed a significant group main effect for
beam balance latencies over 5 days post-injury ( p = 0.002)
(Fig. 1C). None of the injured groups differed from each other,
however. While the CCI +VEH and CCI + low dose EPO treatment
significantly differed from the sham group, the CCI + high dose
EPO group did not differ from sham—indicating an intermediate
motor benefit of high dose EPO in CCI on beam balance testing.
This resulted in half of the possible points (+1) for this outcome for
the high dose EPO group in the OBTT scoring matrix. A two-way
repeated measures ANOVA revealed a significant group main ef-
fect ( p = 0.001) for beam walking latencies over 5 days post-injury
(Fig. 1D). All injury groups performed significantly worse after
CCI versus sham. There were no significant differences between
any of the treated and untreated injury groups.
PBBI model. Post hoc analysis of neuroscore assessments
revealed significant abnormalities in all injured groups (vs. sham)
that were sustained out to 3 weeks post-PBBI ( p < 0.05) regardless
of treatment (Fig. 1E).
Motor and balance coordination were assessed on fixed-speed
version of the rotarod task (Fig. 1F, G). Repeated measures
ANOVA (four groups · three speeds) revealed significant between-
group effects at 7 days ( p < 0.001) and 10 days post-injury p<
0.001) with significant motor impairment evident across all injured
groups. There was also a significant effect of speed (rpm) at 7 days
( p< 0.001) and at 10 days post-injury ( p< 0.05) but no significant
interaction. Overall mean rotarod latency scores were reduced
by 51 – 7% (PBBI + VEH), 38 – 7% (EPO low dose), and 46 – 8%
(EPO high dose) versus sham ( p< 0.005). Although PBBI rats
treated with the low dose of EPO showed a positive (45– 13%)
trend toward improved performance at 10 days post-injury on the
rotarod task, it was not significant, and the trend was modest
( p= 0.217 vs. PBBI).
Cognitive testing
FPI model. Cognitive function was assessed using a simple
place task (Fig. 2A, B) over 4 days followed by a probe trial
(see pooled analysis data later in the text), then a working memory
test (Fig. 2C, D). For the simple place task or hidden platform task,
sham rats showed decreased latencies over the 4 day testing period.
Both TBI treatment groups had higher latencies than sham and TBI-
VEH treated rats. Repeated measures ANOVA, however, was not
significant for day ( p= 0.174), group ( p = 0.239), or group · day
( p= 0.373). Similar findings were seen in the path length analysis.
Repeated measures ANOVA for path length was significant for
day ( p< 0.001) but not for group ( p= 0.716) and group · day
( p= 0.230).
Drug treatment did not improve learning and memory using this
paradigm. In fact, EPO treated rats performed numerically worse
on this task than untreated or VEH treated TBI rats. There was also
no effect on probe trial with EPO. Note that the probe trial is part of
Table 2. Effects of Erythropoietin on Fluid Percussion Injury Physiology
Group Sham TBI-Vehicle TBI-5000 IU/kg TBI-10,000 IU/kg
Pre-TBI
pH 7.43 – 0.01 7.45 – 0.01 7.43 – 0.01 7.41 – 0.01
pO2 (mm Hg) 152.2 – 8.62 156.8– 8.95 157.4– 4.29 158.0 – 8.92
pCO2 (mm Hg) 40.51 – 0.97 40.3 – 1.21 40.96– 1.00 43.48 – 0.59
MAP (mm Hg) 123.73 – 3.75 129.1– 4.11 125.65– 2.94 131.8 – 3.56
Brain temp (C) 36.6 – 0.06 36.0 – 0.04 36.7 – 0.05 36.7 – 0.05
Body temp (C) 36.8 – 0.07 36.7 – 0.07 36.8 – 0.07 36.8 – 0.08
Post-TBI
pH 7.44 – 0.01 7.46 – 0.01 7.44 – 0.01 7.43 – 0.01
pO2 (mm Hg) 147.3 – 10.25 140.2– 6.98 131.1– 7.02 148.8 – 7.16
pCO2 (mm Hg) 40.1 – 0.69 38.33– 0.68 40.19– 1.05 41.52 – 0.71
MAP (mm Hg) 121.76 – 2.48 125.47– 3.11 123.59– 2.88 124.22 – 1.36
Brain temp (C) 36.7 – 0.04 36.7 – 0.05 36.7 – 0.05 36.7 – 0.03
Body temp (C) 36.8 – 0.06 36.8 – 0.06 36.8 – 0.07 36.9 – 0.07
TBI, traumatic brain injury; MAP, mean arterial pressure.
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the pooled analysis data and is presented for all sites in Figure 2I.
One-way ANOVA was not significant for group ( p= 0.810) in the
probe trial. In the working memory task, similar poor cognitive
behavior on a short-term memory task was observed. Repeated
measures ANOVA for working memory latency was significant for
trial ( p < 0.001) and group ( p= 0.037) but not for group · trial.
Student-Newman-Keuls post hoc analysis was significant
( p < 0.05) when comparing location tomatch trials collapsed across
groups because the rats showed improvement in locating the hidden
platform during the second paired trial. There were no significant
differences between groups, however. EPO treated rats showed a
trend toward worse performance on this task versus sham or TBI-
VEH groups. Similar results were seen for the working memory
path length analysis. Repeated measures ANOVA for working
memory path length was significant for trial ( p< 0.003) but not for
group or group · trial. Student-Newman-Keuls post hoc analysis
was significant ( p< 0.05) for path length between the location to
match trial collapsed across all groups. This only indicates that the
rats were performing better from the first trial to the second trial in
the pairing.
CCI model. For the hidden platform MWM task (Fig. 2E),
two-way repeated measures ANOVA for latency revealed a sig-
nificant group main effect ( p= 0.004). Swim latencies across days,
however, did not differ between the injured groups regardless
of treatment. While swim latencies between the sham and TBI +
VEH group only came close to reaching statistical significance
( p= 0.052), there were significant differences between the sham
and both EPO-treated groups—indicating an intermediate detri-
mental effect of EPO on this outcome. This intermediate detri-
mental effect resulted in negative half (-2.5) of the total points that
could be awarded for this task for both EPO doses in the OBTT
scoring matrix. The probe trial also showed no effect on im-
provement with EPO (Fig. 2I). One-way ANOVA was significant
for group ( p = 0.001) in the probe trial with all injury groups sig-
nificantly worse than sham.
PBBI model. Spatial learning performance and thigmotaxic
behavior (% time spent circling the outer perimeter of the maze) are
represented in Figure 2 F, G, respectively. Repeated-measures
ANOVA on latency to locate the hidden platform was significant
FIG. 1. Sensorimotor outcome. Fluid percussion injury (FPI) model (A,B): Bar graphs show the results of (A) spontaneous forelimb
assessment and (B) the gridwalk task. Controlled cortical impact (CCI) model (C,D): Line graphs show the results of the beam balance
and walking task: (C) the total time each animal remained on the elevated beam and (D) the mean time taken to traverse the beam.
Penetrating ballistic-like brain injury (PBBI) model (E–G): Graphs showing results from (E) neuroscore evaluations and (F,G) the
fixed-speed rotarod task. Overall, high dose EPO treatment showed only modest benefit on beam balance in the CCI model. Please see
text for details. Data represent group means – standard error of the mean.
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for group ( p< 0.001) and for trial ( p < 0.001) but not for group ·
trial interaction ( p = 0.054). Post hoc analysis revealed significant
abnormalities in all injured groups with average escape latency
(across all testing days) increased by 147– 13% (PBBI + VEH),
124 – 15% (EPO-5000 IU/kg), and 115– 11% (EPO-10,000 IU/kg)
versus sham (Fig. 2F; p < 0.05). Although both EPO-treated groups
tended to perform better than PBBI + VEH, no significant benefits
of EPO were detected on any MWM parameter. Repeated-
measures ANOVA on percent time spent circling the outer pe-
rimeter of the maze was significant for group ( p< 0.001) and for
trial ( p< 0.001) but not for group · trial interaction ( p= 0.46). Post
hoc analysis showed that all injured groups spent a significantly
greater percentage of time circling the outer perimeter of the maze
versus sham (Fig. 2G; p< 0.05).
ANOVA results on the probe trial were significant ( p < 0.001)
again, with all injured groups spending significantly less time
searching the target (missing platform) zone versus sham (Fig. 2I;
p < 0.05). Although drug-treated PBBI rats (both doses) tended to
perform better than PBBI-VEH across all parameters, no significant
therapeutic benefits of EPOwere detected on anyMWMparameter.
Pooled analysis of therapeutic effects across OBTT
For ease of comparison of the major findings, we present a
pooled analysis of four key outcomes in OBTT—namely, average
latency to find the hidden platform, probe trial, lesion volume, and
tissue loss (Fig. 2H, I and 3A, B).
Cognitive outcomes. Figures 2H, I show the effect of EPO
treatment across all models in OBTT for average latency across
days and probe trial, respectively. For MWM average latencies,
both CCI and PBBI models exhibited significant deficits after in-
jury compared with sham ( p< 0.05). In addition, as anticipated
from the previous analyses, both doses of EPO showed no im-
provement in cognitive function versus TBI - VEH. Average la-
tency across all testing days for FPI did not show a deficit in the
TBI-VEH rats; thus, a somewhat more severe injury level may have
been more optimal in FPI for this task.
The MWM probe trial followed a similar pattern with no benefit
of EPO after TBI across models. Specifically, both CCI and PBBI
models exhibited significant reductions in percent time in the target
quadrant on this task; however, once again there was no effect of
EPO treatment—although there was a trend toward benefit of EPO
in the PBBI model. Once again, FPI did not show a deficit on this
task, suggesting the need for a more severe injury level.
Histological outcomes. Cross model comparisons of gross
histopathological measurements are shown for FPI, CCI, and PBBI
in Figure 3A, B. Lesion volume was analyzed using one-way
ANOVA as a percentage of the contralateral hemisphere in CCI and
PBBI and as a percentage of the contralateral cortex in FPI
(Fig. 3A). Similarly, hemispheric volume loss was analyzed as a
percentage of tissue loss in the injured versus noninjured hemi-
sphere in CCI and PBBI and as a percentage of contralateral cortex
in FPI (Fig. 3B).
FIG. 1. (Continued).
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FIG. 2. Cognitive outcome. Fluid percussion injury (FPI) model (A–D): Graphs show spatial learning performance in the Morris water
maze (MWM) task based on (A) latency and (B) path length to locate the hidden platform over 4 days of MWM testing. Working
memory performance is represented by graphs showing the difference in (C) mean latency and (D) mean distance taken to reach the
hidden platform between the ‘‘location to match’’ trials. Controlled cortical impact (CCI) model (E): Line graph showing the (E) latency
to the hidden platform over 5 days of MWM testing and (F) mean swim latencies to the ‘‘visible’’ platform on post-injury days 19 and
20. Penetrating ballistic-like brain injury (PBBI) (F, G): Graphs showing (F) mean latency to the hidden platform and (G) percent time
spent circling the outer perimeter of the maze (thigmotaxic response) over 5 days of MWM testing. Pooled comparisons (H, I): Graphs
show (H) the mean overall spatial learning performance (latency to locate the hidden platform) and (I) the percent time searching the
target zone during the probe (missing platform) trial. Overall, both doses of EPO showed modest detrimental effects on MWM
performance in the CCI model. Please see text for details. Data represent group means – standard error of the mean; * p < 0.05 compared
with sham.
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FPI model. In the FPI model, there were no significant dif-
ferences in lesion volume or cortical volume loss (a % of contra-
lateral cortex), despite the fact that there was more cortical tissue loss
ipsilateral to injury in all TBI groups (treated or VEH) versus sham.
CCI model. In the CCImodel, lesion volumes ranged between
*8–9% of the contralateral hemisphere across all three TBI groups,
and ANOVA did not differ significantly between groups. Similarly,
hemispheric tissue loss was remarkably consistent at*21–22% of
the contralateral hemisphere in all three injury groups, which was in
each case (ANOVA and Student-Newman-Keuls test) significantly
different versus sham ( p< 0.05). No treatment effect was seen
in CCI.
PBBI model. In the PBBI model, ANOVA revealed a sig-
nificant between-group difference on measures of lesion volume
( p < 0.05) with post-injury administration of EPO (low dose only;
0.50mL/kg) producing a significant and marked (>2X) increase in
mean lesion volume versus PBBI + VEH (PBBI = 32 – 4mm3;
*EPO low dose = 67– 14mm3; EPO high dose = 42 – 7mm3;
*p < 0.05 vs. PBBI). This deleterious effect resulted in a full -2.0
points for low dose EPO in the OBTT scoring matrix. One-way
ANOVA conducted on percent hemispheric tissue loss also re-
vealed a significant main effect ( p< 0.001) with all injured groups
showing significant hemispheric tissue loss compared with sham
(*PBBI + VEH = 24– 1%; *EPO low dose = 32 – 4%; *EPO high
dose = 25– 2%; *p < 0.05 compared with sham). Despite a similar
trend toward greater tissue loss with low dose EPO, however,
neither dose had a significant effect on hemispheric tissue loss
versus VEH.
Biomarker assessments
Circulating biomarker level assessments in rats from the study of
the effect of EPO in OBTT were made with blood samples suc-
cessfully collected from 135 of the 140 rats in this study. Effects of
EPO on post-injury TBI circulating biomarker (UCH-L1 and
GFAP) levels are shown in Figures 4A-C and 5A-C.
FPI model. A Kruskal-Wallis test revealed a significant main
effect on GFAP levels at both 4 h and 24 h post-injury ( p = 0.0001
and p = 0.002, respectively), with all injured groups showing sig-
nificant increases in GFAP versus sham but no evidence of an EPO
treatment effect (Fig. 4A). Consistently, delta 24–4 h GFAP levels,
which measure the decay of serum GFAP levels from 4 h to 24 h,
did not differ between TBI-VEH and TBI treatment groups for
either dose (Fig. 5A). Unlike GFAP, no significant between-group
effects for any TBI group versus sham were seen for post-injury
FIG. 2. (Continued).
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FIG. 3. Histopathology. Bar graphs showing cross-model pooled comparisons of (A) lesion volume as a percent of the contralateral
cortex in fluid percussion injury (FPI) and hemisphere in controlled cortical impact (CCI) and penetrating ballistic-like brain injury
(PBBI), and (B) tissue loss; cortical tissue loss in FPI (as a percent of contralateral cortex) and hemispheric tissue loss in CCI and PBBI
(as a percent of contralateral hemisphere). Overall, low dose EPO showed a statistically significant detrimental effect on lesion volume
in the PBBI model. Please see text for details. Data represent group means – standard error of the mean; * p< 0.05 compared with sham.
FIG. 4. Box plots illustrating glial fibrillary acidic protein (GFAP) and ubiquitin C-terminal hydrolase-L1 (UCH-L1) levels at 4 h and
24 h post-injury. GFAP and UCH-L1 concentrations at 4 and 24 h post-injury in fluid percussion injury (FPI) (A), controlled cortical
impact (CCI) (B), and penetrating ballistic-like brain injury (PBBI) (C). The black horizontal line in each box represents the median,
with the boxes representing the interquartile range. Whiskers above and below the box indicate the 90th and 10th percentiles. Each
individual value is plotted as a dot superimposed on the graph. Overall, at 4 h, high dose EPO increased UCH-L1 levels versus VEH in
CCI, and at 24 h both doses of EPO exacerbated the increase in GFAP levels in PBBI. *( p < 0.05), **( p< 0.01), or ***( p< 0.001) vs.
sham group. #( p0.05) TBI + VEH group vs. high dose EPO group. Please see text for details.
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levels of UCH-L1 at 4 h or 24 h (Fig. 4A). Delta 24–4 h UCH-L1
levels also showed no evidence of a treatment effect (Fig. 5A).
CCI model. Similar to FPI, significant between-group effects
on post-injury levels of GFAP were detected at 4 h ( p< 0.0001) and
24h ( p< 0.0001), with all three injured groups showing significantly
elevated levels at both time points versus sham, but again no treat-
ment effect (Fig. 4B). The overall analysis of delta 24–4 h GFAP
levels comparing the injured groups also revealed no significant ef-
fect of group. While all three injured groups were not significantly
different from sham groups for post-injury serum levels of UCH-L1
at 4 h or 24h, surprisingly, levels of UCH-L1 at 4 hwere significantly
higher in the high dose EPO group versus the CCI + VEH group. In
contrast, levels of UCH-L1 at 24 h were lower in the high dose EPO
group versus the CCI + VEH group (median 0.15 vs. 0.36 ng/mL),
although it did not reach statistical significance (Fig. 4B). As a result,
delta 24–4 h UCH-L1 levels in the high dose EPO group differed
significantly versus the CCI + VEH group ( p= 0.007). This suggests
a beneficial effect of EPO on UCH-L1 net clearance between 4 and
24h after CCI and thus a full positive point for high dose EPO on this
parameter in the OBTT scoring matrix (Fig. 5B).
PBBI model. The overall analysis revealed a significant main
effect on GFAP levels at 4 h post-injury ( p< 0.0001), with all in-
jured groups showing significant increases in GFAP versus sham
but no evidence of a treatment effect. Significant between-group
effects on post-injury levels of GFAP were also detected at 24 h
( p= 0.003), but only low and high dose EPO treatment groups
showed significant increases versus sham ( p = 0.001 and p= 0.047,
respectively, Fig. 4C). This produced negative 0.5 point values for
this parameter for both doses of EPO in this model in the OBTT
scoring matrix. No significant between-group effects on delta 24–
4 h GFAP levels were found (Fig. 5C). There was a significant
between-group effect on post-injury levels of UCH-L1 at 4 h
( p= 0.023), with a significantly higher value in the low dose
treatment versus sham ( p= 0.013, Fig. 4C). There were no signif-
icant group differences on either post-injury levels of UCH-L1 at
24 h or delta 24–4 h UCH-L1 levels (Fig. 4C and 5C).
OBTT outcome scoring matrix
The overall scoring matrix is shown in Table 3 for the effect of
EPO across all models. Overall low dose EPO was deleterious,
receiving a net negative 5.0 points, which was the result of negative
points in the CCI and PBBI models, notably lesion volume in the
PBBI model. High dose EPO received a net negative overall 1.0
points for efficacy across models. Surprisingly, no model showed a
positive overall effect for EPO at either dose.
FIG. 5. Box plots illustrating delta (24–4 h) glial fibrillary acidic protein (GFAP) and ubiquitin C-terminal hydrolase-L1 (UCH-L1)
biomarker levels. Delta 24–4 h GFAP and UCH-L1 levels in fluid percussion injury (FPI) (A), controlled cortical impact (CCI) (B), and
penetrating ballistic-like brain injury (PBBI) (C). The black horizontal line in each box represents the median, with the boxes
representing the interquartile range. Whiskers above and below the box indicate the 90th and 10th percentiles. Each individual value is
plotted as a dot superimposed on the graph. Overall, high dose EPO significantly reduced delta 24–4 UCH-L1 levels in the CCI model
indicating improved net UCH-L1 clearance. #( p < 0.05). TBI + VEH group vs. high dose EPO group. Please see text for details.
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Discussion
The OBTT consortium tested the effects of EPO in three es-
tablished rat models of TBI. Based on substantial pre-clinical data
indicating that EPO is an endogenous and/or pharmacologic me-
diator of neuroprotection and using a similar dosing regimen to that
used in some of these previous studies,6,11,36 we sought to deter-
mine whether this treatment would be effective across three injury
models that produce a range of injury severities and pathophysio-
logical consequences. Unfortunately, EPO did not demonstrate
significant effects on the outcome measures that were assessed,
which included histopathology, behavioral monitoring, and bio-
marker assessments—and was thus remarkably disappointing in
this regard.
Our findings, however, are consistent with the failure of EPO in a
recently published high quality single center randomized controlled
trial (RCT) in adults with severe TBI.16 This work thus actually
represents the first therapy in OBTT that has been evaluated in a
clinical trial of severe TBI—and our findings are consistent with the
results of that trial.
EPO has a long history of being tested in various models of
TBI. In 2005, Yatsiv and colleagues15 reported that recombinant
human EPO (rhEPO) injected 1 and 24 h after TBI improved
motor and cognitive function. Tissue inflammation, axonal de-
generation, and apoptosis were also reduced with rhEPO (5000
IU/kg) treatment using this mouse model. Lu and associates7 re-
ported in rats that treatment with EPO daily for 14 days starting
1 day after CCI produced improvement in spatial memory and
increases in the number of newly formed neurons.7 These data
suggested that in addition to neuroprotection, EPO treatment also
had the capacity of being a neurorestorative therapy. Both of those
putative properties made EPO a drug for testing by the OBTT
consortium.
In another study, again using CCI injury in rats, Cherian and
coworkers6 reported that EPO (5000 IU/kg) treatments initiated at
5min after injury led to reduced contusion volume and increased
neuronal density in the CA1 and CA3 regions of the hippocampus.
Therapeutic window was carefully evaluated with the beneficial
effects of EPO being optimal when given within a 6 h post-
traumatic time window. Using the lateral FPI model, Hartley and
colleagues36 reported that EPO (5000 IU/kg) treatment at 30min
after injury improved energy metabolism and reduced early indi-
cators of histopathological damage.
In another supportive study, Xiong and associates9 showed that
EPO treatment at 6 h and at 3 and 7 days post-TBI (5000 IU/kg)
reduced contusion volume and cell loss in the dentate gyrus and
improved sensorimotor function and spatial learning performance.9
EPO treatment also enhanced neurogenesis in the injury cortex and
dentate gyrus after CCI injury. Thus, these studies suggest bene-
ficial effects of EPO in two models of TBI commonly used in the
field and also in OBTT.
We also tested EPO in a model of CCI injury and surprisingly
did not observe any significant effect on either behavioral or
histopathological outcomes. As suggested previously, the dose
that we selected was based on the published literature. Thus, we
evaluated both a low dose (5000 IU/kg) and a high dose (10,000
IU/kg) given 15min after injury. One question with EPO that
remains controversial is the optimal duration of therapy. With
sustained therapy, there has been concern related to the devel-
opment of polycythemia and hyperviscosity, which is a well-
known limiting side effect, particularly in stroke trials.37 Recent
studies, however, have indicated that delayed treatment with EPO
up to 24 h provides dose-dependent neurorestoration and im-
provement in functional recovery.7,21
In the present study, although we provided the drug within the
established therapeutic window, significant effects were not seen.
Whether or not multiple doses would have mediated a more robust
or beneficial effect is unclear. In a study by Xiong and coworkers,11
the beneficial effects of a single dose compared with a triple dose of
EPO were examined in a rat model of CCI injury. EPO 5000 IU/kg
in saline was therefore administered on day 1 or on days 1, 2, and 3.
Although, histopathological improvement was seen in both treat-
ment paradigms, the triple dose delayed EPO treatment showed
better histopathological and functional outcomes in rats with TBI.
Indeed, some suggest that EPO’s beneficial effect is greatest
seen commonly in experiments where multiple treatments of EPO
are given.20 Given the potential controversy with prolonged ther-
apy for clinical translation and the demonstrated efficacy of even
single dose therapy, we tested whether a single dose of EPO would
be effective across three different TBI models.
Many experiments have been conducted to elucidate mecha-
nisms by which EPO may be protective against TBI. Bian and
colleagues38 evaluated the effects of EPO in a modified Feeney
model and reported that EPO treatment reduced S100B and in-
terleukin 6 levels. They suggested that one mechanism by which
EPO was improving outcome was by decreasing the inflammatory
response in the brain. EPO has also been shown to affect apoptotic
neuronal death. In a study by Liao and colleagues,24 EPO treat-
ment, again in the Feeney model, reduced Bax mRNA and protein
levels versus VEH treated rats. Also, the number of TUNEL
positive cells was less in the EPO treated animals versus controls.
These authors suggested that a mechanism by which EPO could
have various antiapoptotic effects was with the differential reg-
ulation of genes involved in apoptotic processes. We did not as-
sess hippocampal neuron counts given that it is not part of the
outcome matrix in OBTT. We thus cannot rule out effects on that
outcome parameter.
Other studies have assessed various cell signaling cascades that
may be sensitive to EPO treatment. In a study by Valable and
associates,23 phosphorylation of two protein kinases including
extracellular regulated kinase (ERK-1/-2 and AKT) was measured
along with water content in animals given 5000 IU/kg recombinant
human EPO. EPO treatment decreased the TBI-induced upregula-
tion of ERK phosphorylation, although increased AKT phosphor-
ylation was seen at 2 h after the insult. A reduction in brain edema
was also seen, indicating that the antiedema effect of EPO could be
mediated through early inhibition of ERK phosphorylation.
EPO treatment has also been shown to increase expression of
growth factors including vascular endothelial growth factor
(VEGF). In CCI, Xiong and colleagues14 reported that delayed
EPO treatment (5000 IU/kg) at 1, 2, and 3 days after injury im-
proved sensorimotor and cognitive functional recovery as well as
increased brain VEGF expression and phosphorylation of VEGF
receptor-2. This suggested EPO mediated neurological recovery
and vascular remodeling after TBI by engaging VEGF/VEGFR2.
Xiong and coworkers12 also showed that EPO treatment reduced
cortical tissue damage and hippocampal cell loss as well as im-
proving spatial learning in mice that lack the EPO receptor (EPOR)
in both neural and nonneural cells in the brain. EPO treatment was
also shown in the EPOR-null mouse to upregulate antiapoptotic
proteins (p-AKT and Bcl-XL), thus suggesting that EPO may
provide neuroprotection after TBI via vascular events. We did not
assess brain edema, cerebral blood flow (CBF), or the other mo-
lecular mechanisms in our studies, given the mandate in OBTT
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drug screening to focus on key behavioral and histological out-
comes rather than mechanism.
An interesting characteristic of EPO administration is that it
increases angiogenesis and neurogenesis.11 Several studies have
reported that EPO treatment promotes cellular proliferation in the
hippocampus associated with increased NeuN positive cells, indi-
cating evidence of neurogenesis.7 In addition, EPO has been re-
ported to increase blood vessel formation after TBI that may
improve CBF.
EPO has not been translated to benefit in clinical TBI, however,
as evidenced in the aforementioned recent RCT. In addition to that
trial, EPO has been tested in some other TBI clinical studies. In a
study by Nirula and associates39 in which EPO was tested in a
randomized trial of patients with TBI, baseline and daily serum
S100B and neuron-specific enolase (NSE) levels were measured.
Compared with placebo treated patients, EPO treatment did not
alter NSE or S100B levels.
Another clinical trial has suggested that EPO may reduce mor-
tality in severely injured medical or surgical patients.40 In that
study, epoetin alfa (40,000 IU) was administered weekly for a
maximum of 3 weeks with the primary end-point being a per-
centage of patients who received red blood cell transfusion, mor-
tality, and change of hemoglobin concentration. Mortality rate was
lower by day 28 among patients who received epoetin alfa versus
placebo. That study did not focus on TBI, however.
Previous studies have shown that the beneficial effects of EPO
can be separated from the erythropoietic characteristics.41–43 In this
regard, Robertson and and associates44 recently provided new data
for the use of an EPO mimetic peptide in the CCI model in rats. In
that study targeting mild TBI, pyroglutamate helix B surface pep-
tide improved performance on MWM and reduced inflammatory
cell activation by cells labeled with CD68. Ongoing studies con-
tinue to test novel compounds that may be protective but do not
necessarily stimulate erythropoiesis and may therefore be safer for
disorders such as TBI.44
There are some limitations to our study. First, as suggested, we
tested only single early post-TBI administration. Several studies,
however, including those with Chopp and colleagues, gave multi-
ple doses of EPO providing a longer drug exposure compared with
the present OBTT studies.7–9,11,13,14,21 In the recent negative clin-
ical trial, EPO was administered only once in the majority of
subjects because of Food and Drug Administration concerns.16
Nevertheless, some studies have shown EPO efficacy with single
administration.6,11,36,45–48
Second, in the FPI model in this study, the injury level was
insufficient to provide a good target for all aspects of cognitive
outcome. Higher injury levels in FPI can produce unacceptable
mortality from apnea, so these were avoided. Given the importance
of cognitive outcome scoring in OBTT, that may have limited the
chances to show efficacy in FPI.
Another potentially important factor is route of EPO adminis-
tration. While some studies have shown beneficial effects of EPO
given IV, other studies report that intraperitoneal (IP) treatments
are also neuroprotective. The method of injecting EPO could affect
the temporal profile of blood levels that could potentially lead to
both beneficial as well as detrimental effects. For example, IV
administration could produce potentially toxic levels of a drug early
on that could overshadow more appropriate therapeutic doses in
terms of protecting cells from dying. The method of EPO admin-
istration in the present study differed from those produced with
Chopp and colleagues and by Robertson and coworkers who used
IP administration.7–14,16
Conclusion
Our results indicate that treatment with EPO at two doses pre-
viously reported to be effective in the published literature failed to
provide significant protection and improve functional outcome
across three models of TBI. Treatment was based on published data
where a single treatment dose of EPO given early after TBI had
been shown to be effective in improving outcome. Although we
cannot rule out the possibility that other dosing regimens or more
prolonged treatment could have shown different effects, the general
lack of efficacy of EPO coupled with the recent results of the
clinical RCT of this therapy in severe TBI reduced enthusiasm for
further investigation of this agent within the OBTT mechanism.
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